CLINICAL OUTCOMES: MOVEMENT DISORDERSDEEP BRAIN STIMULATION

The clinical use of implantable deep brain stimulation systems for Parkinson’s disease and essential tremor is supported by clinical studies on DBS therapy for Parkinson's disease, and clinical studies on DBS therapy for tremor.

PARKINSON’S DISEASE: MOTOR FUNCTION

DBS (STN) patients at 24-month follow-up achieved a 20% statistically significant improvement (2.1 hours from baseline) compared to 2% (0.2 hours) with BMT alone in the study of those with recent onset of motor complications. "On" time without troublesome dyskinesia at baseline was 10.3 hours.1,2

DBS patients gained up to 5.2 hours each day compared to 0 hours with BMT in the study of those with longer-standing motor complications at 6 months follow-up. DBS Therapy had a sustained improvement to 24 months with a 5.0 hour gain for STN and a 5.2 hour gain for GPi. "On" time without troublesome dyskinesias at baseline was only 6.4 hours.2

DBS Therapy can reduce "off" time.2

DBS (STN) showed a 39% statistically significant improvement (-1.9 hours from baseline) compared to 2% (-0.1 hours) with BMT alone at 24-months follow-up in the study of those with recent onset of motor complications.1,2

"Off" time for DBS patients was reduced by 2.9 hours each day compared to a reduction of 0.1 hours with BMT at 6-months follow-up in the study of patients with longer-standing motor complications. DBS had a sustained improvement with a reduction of 3.1 hours for STN and 2.8 hours for GPi to 24 months.2

Those with DBS (STN) improved 85% from baseline to 24 months compared to 36% in patients with BMT alone in the study of patients with recent onset of motor complications.1,2

DBS improved 89% from baseline to 6 months compared to 37% in the patients with BMT alone in the study of patients with longer-standing motor complications. 83% of STN patients and 74% of GPi patients improved from baseline to 24 months.2

Parkinson's Disease: Quality of Life

Medtronic DBS along with Parkinson’s medication improves quality of life (based on PDQ-39) at 24-months follow-up.2

DBS (STN) showed a statistically significantly improvement of 26% versus a 1% decline in subjects receiving BMT alone in the study of those with recent onset of motor complications.1,2

STN patients improved by 12.6% and GPi patients improved by 12.5% versus baseline in the study of patients with longer-standing motor complications.2

Patients experienced improvement in various activities of daily living (based on the UPDRS II) at 24-months follow-up.2

DBS (STN) patients experienced a statistically significant 30% improvement in activities of daily living versus baseline in the study of those with recent onset of motor complications.1,2

STN patients improved activities of daily living by 16.9% and GPi patients by 18.8% versus baseline in the study of those with longer-standing motor complications.2